Immuron (NASDAQ:IMRN) Stock Short Interest Report for September

Immuron (NASDAQ:IMRN) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 61,753 shares, a drop of 46.6% from the September 15th total of 115,685 shares. Based on an average daily trading volume, of 109,695 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.8% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immuron in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Immuron Stock Performance

IMRN traded down $0.05 on Friday, hitting $0.98. 21,374 shares of the company were exchanged, compared to its average volume of 755,598. Immuron has a 12 month low of $0.68 and a 12 month high of $2.35. The stock’s fifty day moving average is $1.21 and its 200-day moving average is $1.10.

Immuron (NASDAQ:IMRN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $1.27 million during the quarter.

Immuron Company Profile

Immuron Limited (NASDAQ:IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. Its products are based primarily on antibodies derived from hyperimmune bovine colostrum and are designed to act locally in the gastrointestinal tract rather than enter the bloodstream.

The company’s leading product is Travelan, an oral treatment intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).